Header Logo

Connection

Usman Baber to Aged, 80 and over

Back to Details
This is a "connection" page, showing publications Usman Baber has written about Aged, 80 and over.
Usman Baber
Connection Strength
1.934
Aged, 80 and over
  1. Tailoring Antiplatelet Therapy Intensity to Ischemic and Bleeding Risk. Circ Cardiovasc Qual Outcomes. 2019 01; 12(1):e004945.
    View in: PubMed
    Score: 0.111
  2. Associations Between Chronic Kidney Disease and Outcomes With Use of Prasugrel Versus Clopidogrel in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: A Report From the PROMETHEUS Study. JACC Cardiovasc Interv. 2017 10 23; 10(20):2017-2025.
    View in: PubMed
    Score: 0.101
  3. Effect of Chronic Kidney Disease in Women Undergoing Percutaneous Coronary Intervention With Drug-Eluting Stents: A Patient-Level Pooled Analysis of Randomized Controlled Trials. JACC Cardiovasc Interv. 2016 Jan 11; 9(1):28-38.
    View in: PubMed
    Score: 0.090
  4. Prevalence and impact of high platelet reactivity in chronic kidney disease: results from the Assessment of Dual Antiplatelet Therapy with Drug-Eluting Stents registry. Circ Cardiovasc Interv. 2015 Jun; 8(6):e001683.
    View in: PubMed
    Score: 0.087
  5. Prevalence, impact, and predictive value of detecting subclinical coronary and carotid atherosclerosis in asymptomatic adults: the BioImage study. J Am Coll Cardiol. 2015 Mar 24; 65(11):1065-74.
    View in: PubMed
    Score: 0.085
  6. Aortic stenosis: role of balloon aortic valvuloplasty. Cardiol Clin. 2013 Aug; 31(3):327-36.
    View in: PubMed
    Score: 0.076
  7. Association of chronic kidney disease with atrial fibrillation among adults in the United States: REasons for Geographic and Racial Differences in Stroke (REGARDS) Study. Circ Arrhythm Electrophysiol. 2011 Feb; 4(1):26-32.
    View in: PubMed
    Score: 0.063
  8. Efficacy of modified dual antiplatelet therapy combined with warfarin following percutaneous coronary intervention with drug-eluting stents. J Invasive Cardiol. 2010 Feb; 22(2):80-3.
    View in: PubMed
    Score: 0.060
  9. New Criteria to Identify Patients at Higher Risk for Cardiovascular Complications After Percutaneous Coronary Intervention. Am J Cardiol. 2023 02 15; 189:22-30.
    View in: PubMed
    Score: 0.036
  10. Antithrombotic strategy variability in atrial fibrillation and obstructive coronary disease revascularised with percutaneous coronary intervention: primary results from the AVIATOR 2 international registry. EuroIntervention. 2022 Oct 07; 18(8):e656-e665.
    View in: PubMed
    Score: 0.036
  11. A contemporary simple risk score for prediction of contrast-associated acute kidney injury after percutaneous coronary intervention: derivation and validation from an observational registry. Lancet. 2021 11 27; 398(10315):1974-1983.
    View in: PubMed
    Score: 0.034
  12. Edoxaban versus Vitamin K Antagonist for Atrial Fibrillation after TAVR. N Engl J Med. 2021 12 02; 385(23):2150-2160.
    View in: PubMed
    Score: 0.033
  13. Assessing the Risks of Bleeding vs Thrombotic Events in Patients at High Bleeding Risk After Coronary Stent Implantation: The ARC-High Bleeding Risk Trade-off Model. JAMA Cardiol. 2021 04 01; 6(4):410-419.
    View in: PubMed
    Score: 0.032
  14. Validation of the Academic Research Consortium High Bleeding Risk Definition in Contemporary PCI Patients. J Am Coll Cardiol. 2020 06 02; 75(21):2711-2722.
    View in: PubMed
    Score: 0.031
  15. Comparison of One-Year Outcomes in Patients >75 Versus =75 Years With Coronary Artery Disease Treated With COMBO Stents (From The MASCOT Registry). Am J Cardiol. 2020 07 15; 127:1-8.
    View in: PubMed
    Score: 0.030
  16. Ticagrelor monotherapy beyond one month after PCI in ACS or stable CAD in elderly patients: a pre-specified analysis of the GLOBAL LEADERS trial. EuroIntervention. 2020 Apr 03; 15(18):e1605-e1614.
    View in: PubMed
    Score: 0.030
  17. Bleeding Risk, Dual Antiplatelet Therapy Cessation, and Adverse Events After Percutaneous Coronary Intervention: The PARIS Registry. Circ Cardiovasc Interv. 2020 04; 13(4):e008226.
    View in: PubMed
    Score: 0.030
  18. Long-Term Safety and Efficacy of Durable Polymer Cobalt-Chromium Everolimus-Eluting Stents in Patients at High Bleeding Risk: A Patient-Level Stratified Analysis From Four Postapproval Studies. Circulation. 2020 03 17; 141(11):891-901.
    View in: PubMed
    Score: 0.030
  19. The impact of chronic kidney disease in women undergoing transcatheter aortic valve replacement: Analysis from the Women's INternational Transcatheter Aortic Valve Implantation (WIN-TAVI) registry. Catheter Cardiovasc Interv. 2020 07; 96(1):198-207.
    View in: PubMed
    Score: 0.030
  20. The importance of the Heart Team evaluation before transcatheter aortic valve replacement: Results from the BRAVO-3 trial. Catheter Cardiovasc Interv. 2020 12; 96(7):E688-E694.
    View in: PubMed
    Score: 0.030
  21. Predictors of In-Hospital Mortality after Transcatheter Aortic Valve Implantation. Am J Cardiol. 2020 01 15; 125(2):251-257.
    View in: PubMed
    Score: 0.029
  22. Feasibility of measuring patient-reported health status at time of percutaneous coronary intervention: Results from a single-center quality-improvement initiative. Eur J Prev Cardiol. 2020 12; 27(19):2183-2186.
    View in: PubMed
    Score: 0.029
  23. Deep learning for cardiovascular medicine: a practical primer. Eur Heart J. 2019 07 01; 40(25):2058-2073.
    View in: PubMed
    Score: 0.029
  24. Incidence, predictors and impact of stroke on mortality among patients with acute coronary syndromes following percutaneous coronary intervention-Results from the PROMETHEUS registry. Catheter Cardiovasc Interv. 2020 04 01; 95(5):885-892.
    View in: PubMed
    Score: 0.029
  25. Outcomes by Gender and Ethnicity After Percutaneous Coronary Intervention. Am J Cardiol. 2019 06 15; 123(12):1941-1948.
    View in: PubMed
    Score: 0.028
  26. Impact of Discharge Location After Transcatheter Aortic Valve Replacement on 1-Year Outcomes in Women: Results From the WIN-TAVI Registry. Can J Cardiol. 2019 02; 35(2):199-207.
    View in: PubMed
    Score: 0.028
  27. Impact of coronary artery disease and percutaneous coronary intervention in women undergoing transcatheter aortic valve replacement: From the WIN-TAVI registry. Catheter Cardiovasc Interv. 2019 05 01; 93(6):1124-1131.
    View in: PubMed
    Score: 0.028
  28. Impact of Baseline Atrial Fibrillation on Outcomes Among Women Who Underwent Contemporary Transcatheter Aortic Valve Implantation (from the Win-TAVI Registry). Am J Cardiol. 2018 12 01; 122(11):1909-1916.
    View in: PubMed
    Score: 0.027
  29. Carotid plaque thickness and carotid plaque burden predict future cardiovascular events in asymptomatic adult Americans. Eur Heart J Cardiovasc Imaging. 2018 09 01; 19(9):1042-1050.
    View in: PubMed
    Score: 0.027
  30. 1-Year Clinical Outcomes in Women After Transcatheter Aortic Valve Replacement: Results From the First WIN-TAVI Registry. JACC Cardiovasc Interv. 2018 01 08; 11(1):1-12.
    View in: PubMed
    Score: 0.026
  31. Effects of Body Mass Index on Clinical Outcomes in Female Patients Undergoing Percutaneous Coronary Intervention With Drug-Eluting Stents: Results From a Patient-Level Pooled Analysis of Randomized Controlled Trials. JACC Cardiovasc Interv. 2018 01 08; 11(1):68-76.
    View in: PubMed
    Score: 0.026
  32. Prognostic Relation Between Severity of Diabetes Mellitus (On or Off Insulin)?±?Chronic Kidney Disease with Cardiovascular Risk After Percutaneous Coronary Intervention. Am J Cardiol. 2018 01 15; 121(2):168-176.
    View in: PubMed
    Score: 0.026
  33. Effect of valve design and anticoagulation strategy on 30-day clinical outcomes in transcatheter aortic valve replacement: Results from the BRAVO 3 randomized trial. Catheter Cardiovasc Interv. 2017 Nov 15; 90(6):1016-1026.
    View in: PubMed
    Score: 0.025
  34. Prevalence, correlates, and impact of coronary calcification on adverse events following PCI with newer-generation DES: Findings from a large multiethnic registry. Catheter Cardiovasc Interv. 2018 04 01; 91(5):859-866.
    View in: PubMed
    Score: 0.025
  35. Percutaneous Coronary Intervention Outcomes in Very Elderly Patients From a Single Large-Volume Tertiary Care Center, Specifically Focusing on Nonagenarians. JACC Cardiovasc Interv. 2017 06 26; 10(12):1273-1274.
    View in: PubMed
    Score: 0.025
  36. Three-dimensional volumetric assessment of coronary artery calcification in patients with stable coronary artery disease by OCT. EuroIntervention. 2017 Jun 20; 13(3):312-319.
    View in: PubMed
    Score: 0.025
  37. Impact of pre-existing or new-onset atrial fibrillation on 30-day clinical outcomes following transcatheter aortic valve replacement: Results from the BRAVO 3 randomized trial. Catheter Cardiovasc Interv. 2017 Nov 15; 90(6):1027-1037.
    View in: PubMed
    Score: 0.025
  38. An Algorithm for the Use of Embolic Protection During Atherectomy for Femoral Popliteal Lesions. JACC Cardiovasc Interv. 2017 02 27; 10(4):403-410.
    View in: PubMed
    Score: 0.024
  39. Polygenic Risk Score Identifies Subgroup With Higher Burden of Atherosclerosis and Greater Relative Benefit From Statin Therapy in the Primary Prevention Setting. Circulation. 2017 May 30; 135(22):2091-2101.
    View in: PubMed
    Score: 0.024
  40. Sex-Based Differences in Outcomes With Transcatheter Aortic Valve Therapy: TVT Registry From 2011 to 2014. J Am Coll Cardiol. 2016 Dec 27; 68(25):2733-2744.
    View in: PubMed
    Score: 0.024
  41. Evaluation of the Pooled Cohort Equations for Prediction of Cardiovascular Risk in a Contemporary Prospective Cohort. Am J Cardiol. 2017 Mar 15; 119(6):881-885.
    View in: PubMed
    Score: 0.024
  42. Neurological Outcomes With Embolic Protection Devices in Patients Undergoing Transcatheter Aortic Valve Replacement: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. JACC Cardiovasc Interv. 2016 10 24; 9(20):2124-2133.
    View in: PubMed
    Score: 0.024
  43. Correlates and Impact of Coronary Artery Calcifications in Women Undergoing Percutaneous Coronary Intervention With Drug-Eluting Stents: From the Women in Innovation and Drug-Eluting Stents (WIN-DES) Collaboration. JACC Cardiovasc Interv. 2016 09 26; 9(18):1890-901.
    View in: PubMed
    Score: 0.024
  44. A Simple Disease-Guided Approach to Personalize ACC/AHA-Recommended Statin Allocation in Elderly People: The BioImage Study. J Am Coll Cardiol. 2016 08 30; 68(9):881-91.
    View in: PubMed
    Score: 0.024
  45. Relation of Internal Elastic Lamellar Layer Disruption to Neointimal Cellular Proliferation and Type III Collagen Deposition in Human Peripheral Artery Restenosis. Am J Cardiol. 2016 Apr 01; 117(7):1173-9.
    View in: PubMed
    Score: 0.023
  46. One-year results of the ICON (Ionic versus non-ionic Contrast to Obviate worsening Nephropathy after angioplasty in chronic renal failure patients) Study. Catheter Cardiovasc Interv. 2016 Mar; 87(4):703-9.
    View in: PubMed
    Score: 0.022
  47. Balancing the Risk of Bleeding and Stroke in Patients With Atrial Fibrillation After Percutaneous Coronary Intervention (from the AVIATOR Registry). Am J Cardiol. 2015 Jul 01; 116(1):37-42.
    View in: PubMed
    Score: 0.021
  48. Gender-specific outcomes after balloon aortic valvuloplasty: Inhospital and long-term outcomes. Am Heart J. 2015 Jul; 170(1):180-6.
    View in: PubMed
    Score: 0.021
  49. Effect of bivalirudin on aortic valve intervention outcomes study: a two-centre registry study comparing bivalirudin and unfractionated heparin in balloon aortic valvuloplasty. EuroIntervention. 2014 Jul; 10(3):312-9.
    View in: PubMed
    Score: 0.020
  50. Clustering of acute and subacute stent thrombosis related to the introduction of generic clopidogrel. J Cardiovasc Pharmacol Ther. 2014 Mar; 19(2):201-8.
    View in: PubMed
    Score: 0.019
  51. Coronary artery calcification is inversely related to body morphology in patients with significant coronary artery disease: a three-dimensional intravascular ultrasound study. Eur Heart J Cardiovasc Imaging. 2014 Feb; 15(2):201-9.
    View in: PubMed
    Score: 0.019
  52. Comparison of six risk scores in patients with triple vessel coronary artery disease undergoing PCI: competing factors influence mortality, myocardial infarction, and target lesion revascularization. Catheter Cardiovasc Interv. 2013 Nov 15; 82(6):855-68.
    View in: PubMed
    Score: 0.019
  53. Current periprocedural anticoagulation in transcatheter aortic valve replacement: could bivalirudin be an option? Rationale and design of the BRAVO 2/3 studies. J Thromb Thrombolysis. 2013 May; 35(4):483-93.
    View in: PubMed
    Score: 0.019
  54. The use of vascular closure devices and impact on major bleeding and net adverse clinical events (NACEs) in balloon aortic valvuloplasty: a sub-analysis of the BRAVO study. Catheter Cardiovasc Interv. 2014 Jan 01; 83(1):148-53.
    View in: PubMed
    Score: 0.019
  55. Prognostic significance of elevated baseline troponin in patients with acute coronary syndromes and chronic kidney disease treated with different antithrombotic regimens: a substudy from the ACUITY trial. Circ Cardiovasc Interv. 2012 Apr; 5(2):157-65.
    View in: PubMed
    Score: 0.017
  56. Inverse relationship between body mass index and coronary artery calcification in patients with clinically significant coronary lesions. Atherosclerosis. 2012 Mar; 221(1):176-82.
    View in: PubMed
    Score: 0.017
  57. Female gender and mortality after percutaneous coronary intervention: results from a large registry. Catheter Cardiovasc Interv. 2012 Oct 01; 80(4):514-21.
    View in: PubMed
    Score: 0.017
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.